Analyst Ratings for Rhythm Pharmaceuticals (RYTM)
RYTM Rating Summary
RYTM Price Target Summary
- Highest: $157.00 (Goldman Sachs)
- Lowest: $105.00 (H.C. Wainwright)
- Average: $135.40
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$135.40 (+47.1%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
Avg. $ Target:
$135.40 (+47.1%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/18/2026 | RBC Capital » Updated 5/6/2026 |
Lisa Walter | New Coverage | Outperform (N/A) |
137.00 (136.00) |
102.53 (92.02) |
-10.25% | Details |
| 11/25/2025 | Citi » Updated 3/17/2026 |
Samantha Semenkow | New Coverage | Buy (N/A) |
131.00 (136.00) |
101.74 (92.02) |
-9.55% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
